Search alternatives:
point decrease » point increase (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
36181
DataSheet_2_Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.xls
Published 2022“…At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. …”
-
36182
Image_5_Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.jpeg
Published 2022“…At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. …”
-
36183
Image_4_Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.jpeg
Published 2022“…At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. …”
-
36184
Table_1_Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.xls
Published 2022“…At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. …”
-
36185
Bioreductively Activatable Prodrug Conjugates of Combretastatin A‑1 and Combretastatin A‑4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia
Published 2020“…The related CA1-<i>gem</i>-dimethylnitrothiophene BAPC <b>41</b> was also promising (HCR = 12.5) with complete cleavage (90 min) upon treatment with POR. In a preliminary in vivo dynamic bioluminescence imaging study, BAPC <b>45</b> (180 mg/kg, ip) induced a decrease (within 4 h) in light emission in a 4T1 syngeneic mouse breast tumor model, implying activation and vascular disruption.…”
-
36186
Supplementary Material for: Alterations in Monocyte Phenotypes and Functions after a Hip Fracture in Elderly Individuals: A 6-Month Longitudinal Study
Published 2016“…An elevated expression of CX3CR1 was found only in iM. cM produced elevated quantities of TNFα. There was a transient oxidative burst of production before surgery in iM and a sustained decrease in ncM. …”
-
36187
Illustration of controller breakdown of the scheme in Fig 2 when inflows to <i>A</i> exceed the outflows from <i>A</i>.
Published 2024“…<p>The setpoint of <<i>A</i>> is 2.0. Panel a: <i>A</i> (in black) and <<i>A</i>> (in blue) are shown as a function of time when <i>k</i><sub>1</sub> increases successively from <i>k</i><sub>1</sub>=1.0 (phase 1) to <i>k</i><sub>1</sub>=3.0 (phase 2), and finally to <i>k</i><sub>1</sub>=6.0 in phase 3. …”
-
36188
(A-E) The lead compound can bind to mouse Dnmt3a (PDB: 4U7P ref [18]).
Published 2017“…(<u><b>E</b></u>) The plots show changes in pulling force and the corresponding decrease in the number of dynamic binding interactions within Dnmt3a-inhibitor complex. …”
-
36189
-
36190
-
36191
-
36192
-
36193
-
36194
-
36195
-
36196
Data extracted from included studies for the systematic review and meta-analysis.
Published 2025Subjects: -
36197
Specifications and outcomes of clinical trial studies included in the meta-analysis.
Published 2025Subjects: -
36198
-
36199
-
36200